Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor (IC50 : 55 nM).Xanthine oxidoreductase-IN-5 may be used in studies of acute hyperuricemia.

URAT1 inhibitor 7 is a novel and potent inhibitor of the human uric acid transporter protein URAT1 (IC50:12 nM).URAT1 inhibitor 7 inhibits CYP2C9 with an IC50 of 4.2 μM.URAT1 inhibitor 7 can be used to study hyperuricemia and gout.

Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor (IC50: 26.3 nM).Xanthine oxidoreductase-IN-3 can be used in acute hyperuricemia studies.

Lingdolinurad is a uric acid transporter protein inhibitor targeting hURAT1 for the study of hyperuricemia or gout.

Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor that inhibits XOR with an IC50 value of 29.3 nM.Xanthine oxidoreductase-IN-4 can be used to study hyperuricemia.

Graveobioside A can be used in hyperuricemia and gout-resistant drugs or health foods.

Ruzinurad (WO2020088641, compound I) is a potent URAT1 inhibitor, exhibiting high selectivity. This compound shows great promise for investigating hyperuricemia.

LSPN451 is an effective xanthine oxidase inhibitor and may be used to treat hyperuricemia and gout.

Topiroxostat-d4 is a deuterated compound of Topiroxostat. Topiroxostat has a CAS number of 577778-58-6. Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.

Xanthine oxidase-IN-6, a potent and orally active mixed-type inhibitor of xanthine oxidase (XOD), demonstrates significant anti-hyperuricemia and renal protective activity with an IC50 value of 1.37 µM.

URAT1 inhibitor 2 is an orally active inhibitor of URAT1 and CYP isozyme with IC50 values of 1.36 μM, 16.97 μM and 5.22 μM for URAT1-mediated 14C-UA uptake, CYP1A2 and CYP2C9, respectively, URAT1 inhibitor 2 is a promising drug candidate for the study of hyperuricemia and gout.

Puliginurad (YL-90148) is a potent and selective inhibitor of urate transporter protein (URAT) with inhibitory effects on uric acid reabsorption.Puliginurad can be used for the prevention and treatment of hyperuricemia and gout.

Verinurad (RDEA3170) (RDEA3170) is an organic anion transporter URAT1 (SLC22A12) inhibitor for the treatment of gout and hyperuricemia.

Nequinate is an anticoccidial agent, preventing coccidiosis .

Erythronic acid, an endogenous carbohydrate metabolite, is instrumental for research into metabolism-associated disorders. It significantly influences both the development and amelioration of hyperuricemia and is associated with mitochondrial dysfunction in cases of transaldolase deficiency [1].

Potassium erythronate is an intrinsic carbohydrate metabolite utilized in researching metabolic diseases. It significantly influences the development and mitigation of hyperuricemia and associates with mitochondrial dysfunction in transaldolase deficiency [1].

Compound BDEO (URAT1&XO inhibitor 2) serves as a dual-action inhibitor targeting both xanthine oxidase (XO) and URAT1, demonstrating an IC50 value of 3.3 μM for XO inhibition. It effectively impedes uric acid uptake in HEK293 cells with URAT1 expression, evidenced by a Ki of 0.145 μM. In hyperuricemic mice models, the compound has been shown to reduce serum urate levels and uric acid excretion, indicating potential utility for hyperuricemia research [1].

Febuxostat hemihydrate is a xanthine oxidase inhibitor used to treat hyperuricemia and chronic gout.

Allopurinol (Zyloric) is a Xanthine Oxidase Inhibitor. The mechanism of action of allopurinol is as a Xanthine Oxidase Inhibitor.

Allopurinol Sodium is a xanthine oxidase inhibitor with an IC50 of 7.82±0.12 μM.

URAT1&XO Inhibitor 1 (compound 29) serves as a dual inhibitor with IC50 values of approximately 10 μM for URAT1 and 1.01 μM for Xanthine Oxidase. It induces a hypouricemic effect in the potassium oxonate-induced hyperuricemic rat model and is utilized in research pertaining to hyperuricemia [1].

Epaminurad HCl is a URAT1 inhibitor with partial inhibition of OAT1 and OAT3 (organic anion transporters).Epaminurad HCl is a pro-uric acid excretory agent used for the prevention and treatment of gout and hyperuricemia.

Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent inhibitor of xanthine oxidase(XO) with an IC 50 of 0.039 μM that can be used in the research of hyperuricemia and gout. Xanthine oxidase-IN-4 shows hypouricemic potency in potassium oxonate induced hyperuricemia rats. [1].

Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad inhibits OAT1 and OAT3 (organic anion transporter) quite modestly. Epaminurad is a uricosuric agent which can be used for gout and hyperuricemia research [1].

URAT1 inhibitor 1 (1g) is an inhibitor of uric acid transporter 1 (URAT1) (IC50: 32 nM), has the potential to treat hyperuricemia associated with gout.

Irtemazole (R 60844) is a novel uricosuric substance that is valuable in the treatment of hyperuricemia and gout.

Topiroxostat (FYX-051) is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.

Xanthine oxidase-IN-7 (compound1h) is a potent andorally active xanthine oxidase(XO) inhibitor (IC50 = 0.36 μM). Xanthine oxidase-IN-7 effectively reduces serum uric acid levels which has the potential in the hyperuricemia and gout research [1].

JTT-552, a uric acid transporter 1 (URAT1) inhibitor, is used potentially for the treatment of hyperuricemia.

Febuxostat (TEI 6720) is a xanthine oxidase Inhibitor.

URAT1 Inhibitor 5 (compound 16) serves as a powerful inhibitor of URAT1 and is utilized in hyperuricemia research [1].

Febuxostat (TEI 6720) sodium has the potential in gout and hyperuricemia research which is a potent, selective and non-purine inhibitor of xanthine oxidase (XO) with a Ki value of 0.6 nM [1] [2] [3].

Olsalazine-13C6is intended for use as an internal standard for the quantification of olsalazine by GC- or LC-MS. Olsalazine is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.1In vitro, olsalazine increases ion transport in isolated rabbit distal ileum when applied to the luminal side (ED50= 0.3 mM) and stimulates fluid transport in rat jejunum when used at a concentration of 5 mM.2,3Olsalazine (150 mg/kg for 8 days) improves stool consistency and decreases occult and gross bleeding as well as myeloperoxidase (MPO) activity and leukotriene B4levels in colon tissue in a mouse model of acute colitis induced by dextran sulfate .4Olsalazine also inhibits bovine xanthine oxidasein vitro(IC50= 3.4 mg/L) and lowers serum uric acid levels in a mouse model of hyperuricemia induced by oxonic acid when administered at a dose of 20 mg/kg.5Formulations containing olsalazine have been used in the treatment of inflammatory bowel disease (IBD) and ulcerative colitis. 1.Nugent, S.G., Kumar, D., Rampton, D.S., et al.Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugsGut48(4)571-577(2001) 2.Pamukcu, R., Hanauer, S.B., and Chang, E.B.Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acidGastroenterology95(4)975-981(1988) 3.Mohsen, A.Q.M., Mulvey, D., Priddle, J.D., et al.Effects of olsalazine in the jejunum of the ratGut28(3)346-352(1987) 4.Murthy, S., Murthy, N.S., Coppola, D., et al.The efficacy of BAY y 1015 in dextran sulfate model of mouse colitisInflamm. Res.46(6)224-233(1997) 5.Niu, Y., Li, H., Gao, L., et al.Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activityJ. Pharmacol. Sci.135(3)114-120(2017)